ZMapp, an experimental drug being tested against Ebola, has won fast-track status to get quicker Food and Drug Administration approval.
The drug, which made headlines when some high-profile American Ebola patients tried it out, is still being tested in Liberia, where there haven't been any cases of Ebola in months, as well as in Sierra Leone and Guinea.
ZMapp is best known as the drug given to the first U.S. Ebola patient, Dr. Kent Brantly — the medical missionary air-evacuated from Liberia for treatment in the U.S.
No comments:
Post a Comment